FX.co ★ Lilly Reports Positive Phase 3 EMBER-3 Study Data In Advanced Breast Cancer

Eli Lilly and Company (LLY) has announced findings from its Phase 3 EMBER-3 study, evaluating its investigational drug imlunestrant for patients with advanced breast cancer. This study specifically included patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. Participants were randomly assigned to receive either imlunestrant alone, a standard endocrine therapy, or a combination treatment with Lilly's breast cancer medication, Verzenio.

The results revealed that imlunestrant, when used as a standalone treatment, significantly decreased the risk of disease progression or death by 38% in patients with ESR1 mutations compared to the standard endocrine therapy. Furthermore, the combination therapy of imlunestrant and Verzenio reduced the risk of progression or death by 43% compared to imlunestrant alone, applicable to all patients irrespective of their ESR1 mutation status.

In addition to the EMBER-3 study, imlunestrant is also undergoing evaluation in the Phase 3 EMBER-4 study for early breast cancer.